跳至主要内容
临床试验/NCT01238471
NCT01238471已完成1 期

Oral Propranolol Versus Placebo for Early Stages of Retinopathy of Prematurity (ROP): A Pilot, Randomized and Prospective Study.

Rambam Health Care Campus4 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2010年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
20
试验地点
4
主要终点
Regression of Retinopathy of Prematurity (ROP) in Premature Infants by Propranolol Therapy

研究概览

简要总结

In premature infants, propranolol (Prop) treatment might suppress continuing neo-vascularization (NV) and decelerate the progression of retinopathy of prematurity (ROP) towards its severe stages (III-V), thus avoiding the need of interventions (CRYO and/or LASER photo-coagulation of the ischemic retina and preventing severe ocular sequelae. We therefore plan to prospectively investigate the influence of prop versus placebo in VLBW infants with ROP stage 1 (zone I), with stage 2 or higher (any zone) or with Plus disease, along with close follow up regarding safety of prop administration and its effect on ROP.

详细描述

Retinopathy of prematurity (ROP) affects the retinal microvasculature, mostly of very-low-birth-weight (VLBW: < 1500g) premature infants, and is a significant complication of extreme prematurity leading sometimes to devastating consequences. Although ROP is usually mild with no harm, it happens not very rarely to be aggressive causing neo-vascularization (NV) in the immature retina that at times can progress to severe fibrovascular proliferation, retinal detachment and blindness (1). Major risk factors for ROP are low gestational age, low birth weight, hyperoxia, respiratory distress syndrome (RDS) and intraventricular hemorrhage (IVH) (2) as well as postnatal steroid therapy (3). Of note is one report showing that the use of beta-blocking agents by the mother before birth was found to be associated with the development of ROP (4). However, so far no one reported a similar effect of the postnatal use of beta blockers on ROP.

The incidence of ROP is inversely related to gestational age (GA) and birth weight (BW). The condition develops in 51% of infants with a birth weight (BW) <1700 g (5). In infants weighing less than 1250 g, 50% show some evidence of ROP and 10% progress to stage III ROP. According to the Israeli VLBW-Database in 2007, 23.9% of infants develop ROP (all stages), while 4.8% develop severe ROP (stage III-IV) (4). Worldwide, at least 50,000 children are blind from ROP (2,7). In South Africa it accounts for 10.6% of cases of childhood blindness (8). In the US, annually, 500-700 children become blind due to ROP, and 2100 infants will be affected by cicatricial sequelae, such as myopia, strabismus, as well as late-onset retinal detachment (1).

LASER photocoagulation of the ischemic retina is the therapy of choice for moderate to severe ROP and is required in 19.8%, 7.7%. 1.5% and 0.6% of infants weighing 500-749g, 750-999g, 1000-1249g, 1250-1499g, respectively (2). In Israel, 4% of VLBW infants needed LASER photocoagulation or cryo therapy during 2007 (6).

The pathogenesis of ROP is multifactorial and two pathogenetic theories have been proposed:

(A) One-phase theory: Mesenchymal spindle cells when exposed to extrauterine hyperoxia, develop gap junctions that interfere with normal vascular formation and trigger a neovascular response (9).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
4 Weeks 至 14 Weeks(Child)
性别
All
接受健康志愿者

入选标准

  • Evidence for ROP that might progress and that includes any one of the following:
  • Stage 1 (zone I)
  • Stage 2 or higher (zones I, II or III), or Plus disease. The classification of ROP is according to International Classification of Retinopathy of Prematurity (ICROP) 2005 (40) (Appendix I, with scheme of retina showing zones and clock hours).Zone III ROP is not included since it will always regress spontaneously.

排除标准

  • The presence of one or more of the following conditions at enrollment in the study:
  • More than 10 episodes of bradycardia of prematurity/day (HR< 90 bpm) [
  • Atrio-ventricular (A-V) block [2nd or 3rd degree]
  • Significant congenital heart anomaly [not including patent ductus arteriosus, patent foramen ovale or small ventricular septal defect]
  • Heart failure
  • Hypotension (mean blood pressure <45 mmHg)
  • Hypoglycemia (<50mg/dL)
  • Platelet count <100000/mm3

研究组 & 干预措施

Propranolol

Experimental

Oral propranolol for premature infants allocated to this arm by randomization

干预措施: propranolol (Drug)

Oral sucrose 5%

Placebo Comparator

Placebo: Oral sucrose 5% for premature infants allocated to control arm by randomization

干预措施: sucrose 5% (Drug)

结局指标

主要结局

Regression of Retinopathy of Prematurity (ROP) in Premature Infants by Propranolol Therapy

时间窗: propranolol therapy for up 4 weeks

If ROP regresses without the need for treatment (laser and/or CRYO), this will be considered a favorable outcome. On the other hand, if ROP progresses to require treatment, it will be regarded as an unfavorable outcome. Evidence for regression of ROP was observed by serial retinal examinations performed by ophthalmologists as well as by reduction for the need of invasive interventions such as laser photocoagulation of disease areas in the retina.

次要结局

  • Safety of Propranolol Therapy in Premature Infants(4 weeks of propranolol therapy in premature infants)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验